{"schema_version":"secwatch.filing_event.v1","accession":"0001516551-25-000028","form_type":"8-K","ticker":"SKYE","cik":"0001516551","company_name":"Skye Bioscience, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.857533+00:00","generated_at":"2026-05-24T10:07:35.434680+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Skye Bioscience Q4 net loss $9.7M; Phase 2a obesity trial top-line data accelerated to late Q3 2025","bullets":["Cash $68.4M at Dec 31, 2024; projected runway through at least Q1 2027.","Phase 2a CBeyond trial enrolled 136 patients; interim analysis removed; data expected late Q3/early Q4 2025.","Net loss FY2024 $26.6M vs $37.6M in 2023 (prior year included $21.2M IPR&D charge).","R&D expense FY2024 $18.7M (up from $5.8M) driven by Phase 2 trial and manufacturing costs.","Settled insurance litigation, received $2.0M cash proceeds in Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001516551-25-000028","json":"https://secwatch.observer/filing/0001516551-25-000028.json","markdown":"https://secwatch.observer/filing/0001516551-25-000028.md","text":"https://secwatch.observer/filing/0001516551-25-000028.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1516551/000151655125000028/0001516551-25-000028-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1516551/000151655125000028/skye-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:07:35.434680+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}